Cox John sold $131K of DYN
Cox John (CEO & President) sold 4,986 shares of Dyne Therapeutics, Inc. (DYN) at $26.28 ($0.13M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CEO’s open-market sale of 4,986 shares at $26.2800 on 2026-08-13, with holdings after the trade of 363,165 shares, under a pre-arranged 10b5-1 plan.
Market read
Traders may treat this as a minor sentiment datapoint, but it does not provide new operational or financial information about DYN.
What to watch
The article does not state whether the sale was part of a larger series, the CEO’s total planned volume, or any concurrent company news, limiting inference.
Background
The article is an SEC Form 4 insider transaction disclosure for Dyne Therapeutics, Inc. (DYN).
Ticker impact
Dyne Therapeutics CEO John Cox sold 4,986 shares in an open-market transaction on 2026-08-13 for about $131,032, per Form 4.
Likely limited near-term impact; any effect is typically short-lived unless paired with other company-specific news.
The filing is a primary-source Form 4, but the presence of a pre-arranged 10b5-1 plan reduces the likelihood the sale reflects new negative information.
Market effects
No direct sector read-through; insider sales are common and not specific to Dyne Therapeutics’ pipeline or finances in this text.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with investor skepticism, so traders may watch for follow-on selling or other negative disclosures.
Key entities
- issuerDyne Therapeutics, Inc.
Company whose CEO insider sale is disclosed in the Form 4.
- insiderJohn Cox
CEO and President who sold shares in an open-market transaction.
